At a glance
ClinicalIndex Comparison RecordPhase 1Unknown· 10 target
Drug / intervention
GB491+Letrozoledrug
Likely dose
GB491+Letrozole 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-label, Phase Ib Clinical Trial of GB491 in Combination With Letrozole in Previously Untreated Patients With HR-positive, HER2-negative Advanced Breast Cancer
In Brief
A Phase 1 clinical trial evaluating GB491+Letrozole for Advanced Breast Cancer. Targeting 10 participants across 1 site.
Detailed Summary
GB491-005 is a multicenter, open-label, phase Ib Clinical Trial study to evaluate the safety, pharmacokinetic (PK), pharmacodynamic (PD) activity, and preliminary anti-tumor activity of GB491 in combination with Letrozole in Previously Untreated Patients with HR-positive, HER2-negative Advanced Breast Cancer
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Breast Cancer
CountriesChina
Collaborators--
Timeline
Phase 1UnknownOverdue
20222023202420252026
Enrollment StartJun 2021
First PostedApr 2022
Primary CompletionDec 2023
Study CompletionFeb 2024
TodayJul 2026
First PostedApr 20, 2022
Enrollment StartJun 2, 2021
Primary CompletionDec 12, 2023
Study CompletionFeb 1, 2024
TodayJul 1, 2026
Enrollment to primary: 2.5 yearsPosted 4.2 years ago
Interventions
GB491+Letrozoledrug
Drug：The dose of GB491 is 150 mg, which should be taken with a meal and taken twice daily at approximately the same time each day, approximately 12 hours apart